HSBC Holdings’s Summit Therapeutics SMMT Stock Holding History

HSBC Holdings’s Portfolio SMMT Stock Details SMMT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	–	Sell	-98,766	Closed	-$1.72M	–	3201
2025 Q4	$1.72M	Buy	+98,766	New	+$1.86M	﹤0.01%	1639
2025 Q2	–	Sell	-10,672	Closed	-$204K	–	3222
2025 Q1	$204K	Sell	10,672 -28	-0.3%	-$562	﹤0.01%	2608
2024 Q4	$188K	Buy	+10,700	New	+$207K	﹤0.01%	2736
2020 Q4	–	Sell	-27,342	Closed	-$94K	–	3134
2020 Q3	$94K	Sell	27,342 -123,633	-82%	-$428K	﹤0.01%	2629
2020 Q2	$448K	Sell	150,975 -40,508	-21%	-$140K	﹤0.01%	1908
2020 Q1	$458K	Buy	+191,483	New	+$329K	﹤0.01%	1824

Other funds holding SMMT

BBA

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

VPM

Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return

HSBC Holdings's SMMT Position: Q1 2026 in Review

HSBC Holdings sold out of Summit Therapeutics (SMMT) in Q1 2026, closing a stake of 98,766 shares — an estimated $1.72M sold.

HSBC Holdings first reported a position in SMMT in Q1 2020 and held it in 6 quarters. The position peaked at $1.72M in Q4 2025. 222 funds tracked by Wall St. Rank hold SMMT as of Q1 2026.

HSBC Holdings reported no remaining Summit Therapeutics position as of Q1 2026 after selling out during the quarter.
HSBC Holdings sold 98,766 Summit Therapeutics shares in Q1 2026, an estimated $1.72M.
HSBC Holdings first reported a position in Summit Therapeutics in Q1 2020 and held it in 6 quarters.
HSBC Holdings's Summit Therapeutics position peaked at $1.72M in Q4 2025.
222 funds tracked by Wall St. Rank held Summit Therapeutics as of Q1 2026.

Based on HSBC Holdings's 13F filing for Q1 2026, filed 30 Apr 2026.